Login to Your Account


Singles vs. home runs: Biopharmas face a changing 'paying' field

By Jennifer Boggs
Managing Editor

Wednesday, April 30, 2014
SAN FRANCISCO – Amid all the dealmaking and financing talks at this year's Allicense meeting, one topic continually returned to the surface: the increasingly dicey area of reimbursement.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription